in combination with other cancer therapies, has shown a significant tumor response in patients with HER2-positive advanced gastric cancer. The trial results were presented today at the 2025 ASCO ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

Taiwan needs to revamp research into stomach cancer and increase National Health Insurance (NHI) coverage for targeted ...

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

Swayampakula Ramakanth’s rating is based on promising outcomes from ALX Oncology’s ASPEN-06 Phase 2 study of evorpacept in combination with other treatments for HER2+ gastric cancer patients.

T-DXd is also approved for HER2-positive (IHC 3+ or ISH+) breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction cancers, and carries a tumor-agnostic indication for HER2 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...